Abstract
Nowadays, application of miRNases—artificial ribonucleases aimed at degradation of noncoding RNAs, in particular, miRNAs—represents one of the novel experimental approaches to inhibit tumorigenesis. miRNases integrate in their structure an addressing oligonucleotide, which provides specific binding with miRNA target, and a catalytic group, which promotes cleavage of the RNA substrate. Introduction of chemical modifications to the oligonucleotide domain of miRNases in the region that is complementary to miRNA may significantly increase the hybridization properties and nuclease resistance of this type of compound. However, the influence of such structural changes to the ribonuclease activity of miRNases remains unclear. In this work, to investigate the effect of 2'OMe modifications on the activity of miRNases, we synthesized two types of anti-miRNA-21 conjugates of the peptide [(ArgLeu)2Gly]2 and hairpin oligonucleotides in which 14-mer binding region to the miRNA target was fully or partially modified. It is shown that the introduction of 2'OMe modifications promotes a considerable increase in the affinity of miRNases to miRNA-21 but does not change significantly their nuclease resistance. Full modification of conjugates in the region that is complementary to miRNA negatively affects their ribonuclease activity, whereas partial introduction of 2'OMe nucleotides considerably enhances the cleavage activity of miRNases, which leads to a substantial decrease in the proliferation rate and migration potential of tumor cells, which are determined by the miRNA-21 expression.
Keywords: oligonucleotide–peptide conjugates, oncogenic miRNA, miRNA-21, 2'OMe modification, human epidermoid carcinoma KB-8-5.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Zamaratski, E., Pradeepkumar, P.I., and Chattopadhyaya, J., J. Biochem. Biophys. Methods, 2001, vol. 48, pp. 189–208.
Patutina, O.A., Bichenkova, E.V., Miroshnichenko, S.K., Mironova, N.L., Trivoluzzi, L.T., Burusco, K.K., Bryce, R.A., Vlasov, V.V., and Zenkova, M.A., Biomaterials, 2017, vol. 122, pp. 163–178.
Gaglione, M., Milano, G., Chambery, A., Moggio, L., Romanelli, A., and Messere, A., Mol. BioSyst., 2011, vol. 7, pp. 2490–2499.
Danneberg, F., Ghidini, A., Dogandzhiyski, P., Kalden, E., Stromberg, R., and Gobel, M.V., Beilstein. J. Org. Chem., 2015, vol. 11, pp. 493–498.
Patutina, O.A., Bazhenov, M.A., Miroshnichenko, S.K., Mironova, N.L., Pyshnyi, D.V., Vlassov, V.V., and Zenkova, M.A., Sci. Rep., 2018, vol. 8, p. 14 990.
Mironova, N.L., Pyshnyi, D.V., Shtadler, D.V., Fedorova, A.A., Vlassov, V.V., and Zenkova, M.A., Nucleic Acids Res., 2007, vol. 35, pp. 2356–2367.
Sunami, T., Kondo, J., Hirao, I., Watanabe, K., Miura, K.I., and Takenaka, A., Acta Crystallogr. D. Biol. Crystallogr., 2004, vol. 60, pp. 90–96.
Patutina, O.A., Miroshnichenko, S.K., Mironova, N.L., Sen’kova, A.V., Bichenkova, E.V., Clarke, D.J., Vlassov, V.V., and Zenkova, M.A., Front. Pharmacol., 2019 (in press).
Malek-Adamian, E., Patrascu, M.B., Jana, S.K., Martinez-Montero, S., Moitessier, N., and Damha, M.J., Org. Chem., 2018, vol. 83, pp. 9839–9849.
Lennox, K.A. and Behlke, M.A., Pharm. Res., 2010, vol. 27, pp. 1788–1799.
Choung, S., Kim, Y.J., Kim, S., Park, H.O., and Choi, Y.C., Biochem. Biophys. Res. Commun., 2006, vol. 342, pp. 919–927.
Meschaninova, M.I., Venyaminova, A.G., Zenkova, M.A., Vlassov, V.V., and Chernolovskaya, E.L., Oligonucleotides, 2010, vol. 20, pp. 297–308.
Dowler, T., Bergeron, D., Tedeschi, A.L., Paquet, L., Ferrari, N., and Damha, M.J., Nucleic Acids Res., 2006, vol. 34, pp. 1669–1675.
Laursen, M.B., Pakula, M.M., Gao, S., Fluiter, K., Mook, O.R., Baas, F., Langklaer, N., Wengel, S.L., Wengel, J., Kjems, J., and Bramsen, J.B., Mol. Biosyst., 2010, vol. 6, pp. 862–870.
Miroshnichenko, S.K., Patutina, O.A., Burakova, E.A., Chelobanov, B.P., Fokina, A.A., Vlassov, V.V., Altman, S., Zenkova, M.A., and Stetsenko, D.A., Proc. Natl. Acad. Sci. U. S. A., 2019, vol. 116, pp. 1229–1234.
Rait, V.K. and Shaw, B.R., Antisense Nucleic Acid Drug. Dev., 1999, vol. 9, pp. 53–60.
Damha, M.J. and Ogilvie, K.K., Methods Mol. Biol., 1993, vol. 20, pp. 81–114.
Williams, A., Staroseletz, Y., Zenkova, M.A., Jeannin, L., Aojula, H., and Bichenkova, E.V., Bioconjugate Chem., 2015, vol. 26, pp. 1129–1143.
Silberklang, F., Gillum, A.M., and Rajbhandary, U.L., Methods Enzymol., 1979, vol. 59, pp. 58–109.
Donis-Keller, H., Maxam, A.M., and Gilbert, W., Nucleic Acids Res., 1977, vol. 4, pp. 2527–2538.
Vlassov, A.V., Vlassov, V.V., and Giege, R., Dokl. Akad. Nauk, 1996, vol. 349, pp. 411–413.
ACKNOWLEDGMENTS
We are grateful to M.I. Meshchaninov for the synthesis of oligonucleotides and miRNA-21 and A.V. Vladimirov for help in work with the tumor cell culture.
Funding
This study was supported by the Russian Science Foundation (project no. 19-14-00250) and the basic budgetary financing project no. AAAA-A17-117020210024-8.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interests
The authors declare that they have no conflict of interest.
Statement on the Welfare of Animals
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
Additional information
Translated by M. Batrukova
Corresponding author: phone: +7(383) 363-51-61, fax: +7(383)363-51-53; e-mail: patutina@niboch.nsc.ru.
Rights and permissions
About this article
Cite this article
Miroshnichenko, S.K., Amirloo, B., Bichenkova, E.V. et al. 2'OMe Modification of Anti-miRNA-21 Oligonucleotide–Peptide Conjugate Improves Its Hybridization Properties and Catalytic Activity. Russ J Bioorg Chem 45, 803–812 (2019). https://doi.org/10.1134/S1068162019060281
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1068162019060281